Effects of atorvastatin calcium on serum tumor necrosis factor alpha and C-reactive protein in patients with acute cerebral infarction / 中国医师进修杂志

Objective To observe the effects of atorvastatin calcium on serum tumor necrosis factor alpha (TNF)-α and C-reactive protein (CRP) in patients with acute cerebral infarction (ACI), so as to approach the mechanism of atorvastatin calcium inhibiting ACI inflammatory injury. Methods Eighty-four patients with ACI were randomly divided into 2 groups: group B (42 cases, treated with antiplatelet therapy and improving cerebral circulation), group A(42 cases, treated with atorvastatin calcium 20 mg/d after the onset of ACI for 28 days on the base of group B). TNF- α and CRP were detected before treatment and in the 3rd,7th day after treatment. The European stroke scale (ESS) was evaluated on the same time. A healthy control group (group C, 16 cases) was also included in the study. Results The peak of CRP and TNF-α levels were observed in the 3rd and 7th day after treatment respectively, and the levels of group A were lower than those of group B [(13.00 ± 2.45) mg/L vs (19.21 ± 3.67) mg/L,(19.79 ± 11.01) ng/L vs (30.69 ± 18.47) ng/L, P < 0.05]. In the 7th day after treatment, the scores of ESS was higher in group A than that in group B [(79.19 ± 30.59) scores vs (63.91 ± 27.87) scores, P < 0.05]. Conclusions Atorvastatin calcium can prevent the increase of serum TNF-α and CRP, and it has anti-inflammatory effect. Atorvastatin calcium may have the role of neuroprotection besides lipid-lowering.

Effect of polysaccharide sulfate on plasmatic P- selectin in patient with acute cerebral infarction / 中国医师进修杂志

0.05),but the level of P- selectin in treatment group were obviously decreased compared with control group after the seventh and fourteenth day(P

Effects of Polysaccharide Sulfate on plasma von Willebrand factor and thrombomodulin in patients with acute cerebral infarction / 临床神经病学杂志

Objective To investigate the effects of Polysaccharide Sulfate (PSS) on plasma von Willebrand factor (vWF) and thrombomodulin (TM) in patients with acute cerebral infarction.Methods 64 patients with acute cerebral infarction were randomly assigned to receive intravenous drip of PSS (150 mg/d for 14 days, 32 cases, PSS group) or Troxerutin (600 mg/d for 14 days, 32 cases, control group). All of the patients were tested for plasmatic levels of vWF and TM prior to and at 7 d, 14 d after treatment.Results The levels of vWF in PSS group at 7 d, 14 d after treatment were obviously decreased compared with control group (all P